France

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sanofi and GSK Initiate Phase 1/2 Clinical Trial of Covid-19 Adjuvanted Recombinant Protein-Based Vaccine Candidate

Lead Product(s): Adjuvanted COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Details:

The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sanofi and GSK Land $2.1 Billion Deal With U.S. For Covid-19 Vaccine Development And 100 Million Doses

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: U.S Department of Health and Human Services

Deal Size: $2,100.0 million Upfront Cash: Undisclosed

Deal Type: Partnership July 31, 2020

Details:

Collaborating with the U.S. Department of Health and Human Services and Department of Defense will help fund the development activities and secure scale-up of Sanofi’s and GSK’s manufacturing capabilities in the U.S for the recombinant protein-based, adjuvanted vaccine.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sanofi, Glaxosmithkline in Talks with EU to Secure Covid-19 Vaccine Deal

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: European Union

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 31, 2020

Details:

The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sanofi/GSK Sign Deal with UK Gov for COVID-19 Vaccine

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: UK government

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 29, 2020

Details:

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Sanofi

Sanofi and GSK Initiate Phase 1/2 Clinical Trial of Covid-19 Adjuvanted Recombinant Protein-Based Vaccine Candidate

Sanofi

Sanofi and GSK Land $2.1 Billion Deal With U.S. For Covid-19 Vaccine Development And 100 Million Doses

Sanofi

Sanofi, Glaxosmithkline in Talks with EU to Secure Covid-19 Vaccine Deal

Sanofi

Sanofi/GSK Sign Deal with UK Gov for COVID-19 Vaccine